|
시장보고서
상품코드
2049527
신경퇴행성 질환 치료 시장 보고서 : 적응증별, 약제 종류별, 투여 경로별, 유통 채널별, 지역별(2026-2034년)Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034 |
||||||
세계의 신경퇴행성 질환 치료 시장 규모는 2025년에 818억 달러에 달했습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 4.30%를 기록하며 2034년까지 1,208억 달러에 달할 것으로 예측하고 있습니다.
신경퇴행성 질환은 중추신경계(CNS) 또는 말초신경계(PNS)에서 뉴런의 구조와 기능의 진행성 퇴행을 유발하는 일련의 뇌질환을 말합니다. 현재 신체적 또는 정신적 증상을 완화하고 환자의 삶의 질을 향상시키기 위해 여러 가지 약물을 사용할 수 있습니다. 또한, 연구진은 신경퇴행성 질환을 조기에 발견 및 진단하고 진행을 예방하기 위해 분자진단법, 특히 바이오마커 및 이미징 분광법 개발에 주력하고 있습니다.
과도한 알코올 섭취로 인한 종양 및 뇌졸중 유병률의 증가는 고령화 사회의 진전과 함께 신경퇴행성 질환의 발병 위험을 높이는 주요 요인 중 하나가 되고 있습니다. 이에 따라 알츠하이머병, 파킨슨병, 헌팅턴병, 근위축성측색경화증(ALS) 등 신경퇴행성 질환의 조기 진단을 위한 분자진단 기술의 필요성이 더욱 커지고 있습니다. 이와 더불어, 연구진은 이러한 질환의 분류를 효과적으로 이해하기 위해 신경병리학적인 방법과 분자생물학적 방법을 결합하고 있습니다. 또한, 다양한 종류의 신경퇴행성 질환을 대상으로 한 최소침습(MI) 스크리닝 검사 개발도 진행하고 있습니다. 또한, 많은 국가의 정부 기관과 비정부기구(NGO)는 신경퇴행성 질환의 위험요인에 대한 인식을 높이기 위해 다양한 건강 교육 캠페인을 지원하고 있습니다. 인프라 개선, 가처분 소득 증가에 따른 의료 시설 접근성 향상 등 다른 요인들도 향후 몇 년 동안 시장 성장을 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 세계 신경퇴행성 질환 치료 시장은 지금까지 어떤 추세를 보였으며, 향후 몇 년 동안 어떤 추세를 보일 것인가?
- COVID-19가 세계 신경퇴행성 질환 치료 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 적응증별 시장 현황은 어떠한가?
- 약품 종류별 시장 현황은 어떠한가?
- 투여 경로별 시장 현황은 어떠한가?
- 유통 채널별 시장 현황은 어떠한가?
- 이 산업의 밸류체인에서 각 단계는 무엇인가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 신경 퇴행성 질환 치료 시장의 구조는 무엇이며, 주요 플레이어는 누구인가?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 신경퇴행성 질환 치료 시장
제6장 시장 내역 : 적응증별
제7장 시장 내역 : 약물 유형별
제8장 시장 내역 : 투여 경로별
제9장 시장 내역 : 유통 채널별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSMThe global neurodegenerative disease treatment market size reached USD 81.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 120.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.30% during 2026-2034.
Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.
The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease , Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.
KEY MARKET SEGMENTATION:
Breakup by Indication:
- Multiple Sclerosis
- Parkinson's Disease
- Alzheimer's Disease
- Spinal Muscular Atrophy (SMA)
- Huntington's Disease
- Others
Breakup by Drug Type:
- N-methyl-D-aspartate Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
- Dopamine Inhibitors
- Others
Breakup by Route of Administration:
- Oral
- Injectable
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global neurodegenerative disease treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Neurodegenerative Disease Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Indication
- 6.1 Multiple Sclerosis
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Parkinson's Disease
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Alzheimer's Disease
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Spinal Muscular Atrophy (SMA)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Huntington's Disease
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Drug Type
- 7.1 N-methyl-D-aspartate Receptor Antagonists
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Selective Serotonin Reuptake Inhibitors
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Dopamine Inhibitors
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Biogen
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Boehringer Ingelheim International GmbH
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 F. Hoffmann-La Roche AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.4 GlaxoSmithKline Plc
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 SWOT Analysis
- 15.3.5 Merck & Co. Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Novartis AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Pfizer Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Sanofi S.A
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Teva Pharmaceutical Industries Ltd.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 UCB S.A
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.1 Biogen
